Gyre Therapeutics (GYRE) Accumulated Expenses (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Accumulated Expenses of $15.4 million for Q1 2026, down 10.58% year-over-year from $17.2 million in Q1 2025, and up 7.35% quarter-over-quarter from $14.4 million in Q4 2025.
Gyre Therapeutics (GYRE) Accumulated Expenses (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Accumulated Expenses for 17 consecutive years, with $15.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 10.58% year-over-year to $15.4 million; the TTM figure through Mar 2026 stood at $15.4 million (down 10.58% YoY), while the FY2025 annual figure was $14.4 million, up 35.27% from the prior year.
- Accumulated Expenses advanced to $15.4 million in Q1 2026 per GYRE's latest filing, from $14.4 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $17.2 million in Q1 2025 and bottomed at $708000.0 in Q3 2023.
- Historically, Accumulated Expenses has averaged $8.4 million across 5 years, with a median of $10.5 million in 2024.
- Annual changes were most pronounced in 2022 — Accumulated Expenses slumped 63.79% — and 2024, when it jumped 1360.14%.
- Gyre Therapeutics' Accumulated Expenses stood at $9.3 million in 2022, then grew by 28.83% to $11.9 million in 2023, then declined by 11.06% to $10.6 million in 2024, then jumped by 35.27% to $14.4 million in 2025, then climbed by 7.35% to $15.4 million in 2026.
- Business Quant data shows GYRE's Accumulated Expenses at $15.4 million in Q1 2026, $14.4 million in Q4 2025, and $11.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.81 Mn |
| Mar 31, 2026 | 15.42 Mn |
| Dec 31, 2025 | 14.36 Mn |
| Sep 30, 2025 | 11.80 Mn |
| Jun 30, 2025 | 14.92 Mn |
| Mar 31, 2025 | 17.24 Mn |
| Dec 31, 2024 | 10.62 Mn |
| Sep 30, 2024 | 9.55 Mn |
| Jun 30, 2024 | 10.51 Mn |
| Mar 31, 2024 | 10.77 Mn |
| Dec 31, 2023 | 11.94 Mn |
| Sep 30, 2023 | 708,000.00 |
| Jun 30, 2023 | 720,000.00 |
| Mar 31, 2023 | 1.09 Mn |
| Dec 31, 2022 | 9.26 Mn |
| Sep 30, 2022 | 1.04 Mn |
| Jun 30, 2022 | 911,000.00 |
| Mar 31, 2022 | 2.14 Mn |
| Dec 31, 2021 | 1.47 Mn |
| Sep 30, 2021 | 2.55 Mn |